Genmab ADR (GMAB) — Titan Protect Analysis

GMAB

Genmab ADR

Healthcare · ·

$25.15

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$14.6B

Total market value of the company

Trailing P/E

18.11

Reasonably valued

Forward P/E

12.97

Based on estimated future earnings — lower means cheaper

Rev Growth

+25.3%

Year-over-year revenue change

Profit Margin

21.1%

How much profit the company keeps from each dollar of revenue

ROE

15.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$38.00

+51% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Genmab ADR

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R

https://www.genmab.com

Country: Denmark Employees: 3,088 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.052

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0068

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.194

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-7.3%

Historical annualised return based on price data

Max Drawdown

-37.4%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.70

Less volatile than the market — more defensive

52W High

$35.43

29% below the year high

52W Low

$20.23

24% above the year low

Avg Volume

1,836,298

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$1.31

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

94.18

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

93.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

25.1%

Profit from core operations before interest and tax

Free Cash Flow

$830M

Positive — the business generates more cash than it spends

Revenue (TTM)

$3.9B

Total revenue over the last 12 months

Net Income

$821M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$41.50

Target Median

$38.00

Target Low

$32.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go